Benitec Biopharma closed at $8.97 on Nov 4, up 6.79%, 43.4% below its 52-week closing high. Volume of 78.7K shares was 0.45× its 20-day average (below normal).
Split-adjusted performance: -0.3% over one month, -28.6% over six months, -43.4% over one year.
Short interest was 2.0M shares at the Oct 15 settlement, down 2.3% from the prior report (9.4% of float, 10.1 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BNTCBenitec Biopharma | $8.97 | +6.79% | −28.6% | — | — | — | $313.0M | |
| CYPHCypherpunk Technologies | $2.90 | +11.54% | +156.6% | — | — | — | $312.5M | Compare |
| ENTAEnanta Pharmaceuticals | $10.73 | +3.47% | −29.6% | −21.6% | −135.8% | — | $312.5M | Compare |
| EBSEmergent Biosolutions | $6.06 | −3.12% | −33.5% | −52.4% | −29.7% | — | $310.5M | Compare |
| CGCCanopy Growth | $0.7520 | +6.41% | −34.6% | +7.8% | −18.0% | — | $318.1M | Compare |
| SPRYARS Pharmaceuticals | $3.08 | +0.82% | −66.9% | +114.2% | −185.2% | — | $305.8M | Compare |
| PRLDPrelude Therapeutics Incorporated | $4.08 | +7.94% | −15.7% | — | −244.1% | — | $325.6M | Compare |
| ARCTArcturus Therapeutics Holdings | $10.54 | +10.48% | +15.4% | −89.5% | −803.8% | — | $299.6M | Compare |
| TTRXTurn Therapeutics | $9.84 | +3.47% | +159.3% | — | — | — | $298.8M | Compare |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
